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The present study investigated whether transforming growth
factor-beta 1 (TGF-b1) exerts an autocrine positive effect on
angiotensinogen (ANG) gene expression in rat kidney
proximal tubular cells, and delineates its underlying
mechanism(s) of action. Rat immortalized renal proximal
tubular cells (IRPTCs) and freshly isolated mouse renal
proximal tubules were incubated in the absence or presence
of active human TGF-b1. IRPTCs were also stably transfected
with rat TGF-b1 or p53 tumor suppressor protein (p53)
cDNA in sense (S) and antisense (AS) orientations. ANG
mRNA and p53 protein expression were assessed by
reverse transcription-polymerase chain reaction and Western
blotting, respectively. Reactive oxygen species (ROS)
generation was quantified by lucigenin assay. Active TGF-b1
evoked ROS generation and stimulated ANG mRNA and p53
protein expression, whereas a superoxide scavenger and
inhibitors of nicotinamide adenine dinucleotide oxidase and
p38 mitogen-activated protein kinase (p38 MAPK) abolished
the TGF-b1 effect. Stable transfer of p53 cDNA (S) enhanced
and p53 cDNA (AS) abolished the stimulatory effect of TGF-b1
on ANG mRNA expression in IRPTCs. Our results demonstrate
that TGF-b1 stimulates ANG gene expression and its action is
mediated, at least in part, via ROS generation, p38 MAPK
activation, and p53 expression, suggesting that angiotensin II
and TGF-b1 may form a positive feedback loop to enhance
their respective gene expression, leading to renal injury.
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Transforming growth factor-beta 1 (TGF-b1) is a risk factor
for the initiation and progression of renal disease.1 The
progression of chronic renal disease is correlated with an
increase in TGF-b1 expression in the kidney and is associated
with elevated circulating levels of TGF-b1.2–4 TGF-b1 has
been found to have differential effects on various tissues and
cell lines, including the induction of cell cycle arrest and
cellular hypertrophy.5–8 TGF-b1 also acts on renal proximal
tubular cells, podocytes, and mesangial cells to induce fibrosis
and glomerulosclerosis.9–11 Interestingly, TGF-b1 null mutant
mice show no gross developmental abnormalities at birth,
but succumb to multifocal inflammatory lesions that lead to
organ failure and early death about 20 days after birth.12 On
the other hand, transgenic mice specifically expressing TGF-
b1 in the kidney develop severe glomerulopathy, interstitial
extracellular matrix accumulation, arteriolar hyalinization,
proximal tubule distension, and tubular atrophy.13 Taken
together, these studies indicate that TGF-b1 is a potent
mediator of renal fibrosis and subsequent kidney injury.
More recently, TGF-b1 has been described as an inducer of
apoptosis, and has been found to participate in epithelial to
mesenchymal transition in tubular epithelial cells.14–19 The
underlying mechanism of TGF-b1 action, however, are not
fully understood. It appears that reactive oxygen species
(ROS) may play an important role in mediating the action of
TGF-b1.20–23
We have reported previously that intrarenal angiotensino-
gen (ANG) gene expression and subsequent renin–angiotensin
system activation are essential in mediating the effect of high
glucose on TGF-b1 and collagen a1 (type IV) gene
expression as well as cellular hypertrophy in immortalized
renal proximal tubular cells (IRPTCs).24–26 We have also
reported that the stimulatory effect of high glucose is
mediated, at least in part, via ROS generation and subsequent
activation of p38 mitogen-activated protein kinase (p38
MAPK), protein kinase C, and the hexosamine biosynthesis
pathway.27,28 These data suggest that ROS generation is an
important mediator of the high glucose action that enhances
ANG gene expression and IRPTC hypertrophy.
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The present study was designed to investigate whether
TGF-b1 could enhance ANG gene expression via ROS
generation. Our results reveal that TGF-b1 stimulates
ANG gene expression, at least in part, via enhanced ROS
generation, p38 MAPK activation, and p53 expression.
These observations indicate that angiotensin II (Ang II)
and TGF-b1 could form a positive autocrine feedback loop to
enhance their respective gene expression in vivo, leading to
renal injury.
RESULTS
TGF-b1 induces ANG mRNA and protein expression in IRPTCs
Figure 1a shows that TGF-b1 increased ANG mRNA
expression greater than 200% in IRPTCs after 6–8 h stimu-
lation, with optimal doses at 2 ng/ml (Figure 1b). TGF-b1 at
2 ng/ml with a 8 h incubation period was routinely used in
subsequent experiments.
Figure 2 shows that culture of IRPTCs with TGF-b1 (2 ng/
ml) for 8 h resulted in significantly higher ANG protein
levels than without TGF-b1. These results demonstrate that
TGF-b1 stimulates ANG expression in IRPTCs.
Figure 3 depicts that TGF-b1 (sense (S)) stable transfor-
mants expressed significantly higher ANG mRNA levels in
comparison with TGF-b1 (AS) stable transformants and
controls (IRPTCs stably transferred with the control vector
plasmid replicative E. coli (pRC)/Rous sarcoma virus (RSV)).
These results demonstrate that TGF-b1 stimulates ANG
mRNA expression in IRPTCs.
Effect of TGF-b1 on ROS generation in IRPTCs
Figure 4a shows that treatment of IRPTCs with 2 ng/ml active
TGF-b1 for 5 h in serum-free Dulbecco’s modified Eagle’s
medium (DMEM) resulted a significant increase of ROS
generation within 10 min of measurement and a maximal
increment of 150–200% at 5 min (Figure 4b). Measurement
of ROS generation at 5 min was routinely used in subsequent
experiments.
The addition of tiron (104 M) and diphenylene iodinium
(DPI) (106 M) prevented ROS generation in IRPTCs
stimulated by TGF (Figure 5a). In contrast, neither losartan
(109 M) nor perindopril (109 M) inhibited ROS generation
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Figure 1 | TGF-b1 induces ANG mRNA expression in a time- and
dose-dependent manner. (a) IRPTCs were plated at a density of
1 104 cells in six-well plates in DMEM supplemented with 5% FBS.
When the cells reached two-thirds confluence, the medium was
changed to serum-free DMEM containing 2 ng/ml active TGF-b1. The
cells were collected at different time points for RNA extraction for
RT-PCR of ANG and b-actin mRNA expression. (b) When the cells
reached two-thirds confluence, the 5% FBS medium was changed to
serum-free DMEM containing increasing concentrations (0–10 ng/ml)
of active TGF-b1. The cells were collected after 8 h for RNA extraction
and RT-PCR for ANG and b-actin mRNA expression. The ratio of ANG
mRNA to b-actin mRNA was quantified by Typhoon densitometry.
The graphs represent the mean7s.d. of three independent
experiments and each treatment group was assayed in duplicate.
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Figure 2 | Effect of TGF-b1 on rANG protein expression in IRPTCs.
When the cells reached 60–70% confluence, the medium was
changed to serum-free DMEM with or without 2 ng/ml active TGF-b1
for 8 h. Cells were harvested for protein extraction and then
subjected to Western blotting of ANG and b-actin. The ratio of ANG
to b-actin was quantified by Typhoon densitometry. The graphs
represent the mean7s.d. of three independent experiments and
each treatment group was assayed in triplicate.
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Figure 3 | ANG mRNA expression in IRPTCs stably transfected
with S TGF-b1 or AS TGF-b1 cDNA. When the cells reached
two-thirds confluence, the 5% FBS medium was changed to DMEM
without FBS, and incubated for 8 h for synchronization. Then, 5% FBS
was added to start the experiment. The cells were collected for RNA
extraction after 0 and 48 h incubation, followed by RT-PCR of ANG
and b-actin mRNA expression. The ratio of ANG mRNA to b-actin
mRNA was quantified by Typhoon densitometry. The graph
represents the mean7s.d. of four independent experiments.
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evoked by TGF-b1 in IRPTCs (Figure 5b). However, at
concentrations greater than 108 and 106 M, both losartan
and perindopril, respectively, effectively suppressed ROS
generation stimulated by TGF-b1 (Figure 6). Furthermore,
TGF-b1 (S) stable transformants expressed significantly
higher levels of TGF-b1 mRNA (that is, greater than fourfold,
Po0.005) (Figure 7a) and plasminogen activator inhibitor-1
(PAI-1) mRNA (that is, greater than threefold, Po0.005)
(Figure 7b) in comparison with controls (IRPTCs stably
transferred with the control vector pRC/RSV) and the
addition of tiron and DPI blocked the increment of PAI-1
mRNA expression in TGF-b1 (S) stable transformants.
These results indicate that TGF-b1 action on ROS genera-
tion in IRPTCs is specific and mediated, at least in part,
via nicotinamide adenine dinucleotide oxidase activation
in IRPTCs.
TGF-b1 induces p53 expression in IRPTCs
Studies have demonstrated that TGF-b1 induces p53 tumor
suppression gene protein (p53) expression in several cell
types.29–31 We, therefore, tested whether TGF-b1 could evoke
p53 expression in IRPTCs. Figure 8a shows that TGF-b1
stimulated p53 expression in IRPTCs in a dose-dependent
manner with significant increases (Po0.01) at 0.5 ng/ml
TGF-b1, reaching a maximal effect at 10 ng/ml. To verify
these data, we cultured TGF-b1 (S) stable transformants for
48 h in DMEM with 5% fetal bovine serum (FBS), followed
by Western blotting for p53. Again, TGF-b1 (S) transfor-
mants expressed up to two fold increases (Po0.005) in p53
protein level (Figure 8b). TGF-b1 (antisense (AS)) stable
transformants tended to decrease p53 expression as com-
pared to control, but not reaching statistical significance.
Taken together, these findings strongly suggest that TGF-b1
modulates p53 expression at the protein level.
Effect of p53 on ANG mRNA expression in IRPTCs
The ANG promoter region contains a p53-binding site (from
nucleotides N-599 to N-575, 50-CTT CCA TCC ACA AGC
CCA GAA CAT T-30, upstream of the TATAA box (GenBank
M31673)).32,33 To further investigate whether p53 is involved
in the ANG mRNA expression induced by TGF-b1, we stably
transfected IRPTCs with promoter (p)RSV/p53 (S) and
pRSV/p53 (AS), followed by culture for 24 h in DMEM with
5% FBS or for 24 h in serum-free DMEM in the absence
or presence of TGF-b1. Figure 9a shows that ANG mRNA
expression in p53 (S) stable transformants was at least
two fold greater (Po0.005) than in IRPTCs stably trans-
fected with the control plasmid pRC/RSV. Furthermore, ANG
b
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Figure 4 | Effect of TGF-b1 on ROS generation in IRPTCs. (a) IRPTCs
were plated at 1 104 cells in DMEM supplemented with 5% FBS.
When the cells reached two-third confluence, the medium was
changed to serum-free DMEM containing 2 ng/ml active TGF-b1. The
cells were collected after 5 h of incubation, and ROS generation was
quantified by lucigenin assay for a duration of 20 min. (b) ROS
generation quantified by lucigenin assay at 5 min in IRPTCs that have
been preincubated for 5 h in serum-free medium in the absence or
presence of TGF-b1 (2 ng/ml). The graphs represent the mean7s.d. of
three independent experiments and each treatment group was
assayed in duplicate.
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Figure 5 | Effect of TGF-b1 on ROS generation in IRPTCs in the
presence or absence of DPI, tiron, losartan, and perindopril.
(a) IRPTCs were plated at 1 104 cells in DMEM supplemented with
5% FBS. When the cells reached two-thirds confluence, the medium
was changed to serum-free DMEM containing 2 ng/ml active TGF-b1
in the absence or presence of DPI (106 M) or tiron (104 M). The cells
were collected after 5 h of incubation, and ROS generation was
measured by lucigenin assay. (b) When cells reached two-thirds
confluency, the 5% FBS medium was changed for DMEM without FBS
containing 2 ng/ml active-TGF-b1 in the absence or presence of
losartan (109 M) or perindopril (109 M). Cells were collected after 5 h
of incubation and ROS generation was quantified by lucigenin assay.
The graph represents the mean7s.d. of four independent
experiments and each treatment group was assayed in duplicate.
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mRNA expression in p53 (AS) stable transformants was
significantly lower in the controls (Po0.01). Most interest-
ingly, TGF-b1 further enhanced ANG mRNA expression in
p53 (S) stable transformants (Po0.005) (Figure 9b). In
contrast, TGF-b1 had no significant effect on ANG mRNA
expression in p53 (AS) stable transformants.
Role(s) of p38 MAPK in mediating TGF-b1 action on ANG
mRNA expression
Next, we tested the effect of inhibitors of superoxide
scavenger (tiron) and nicotinamide adenine dinucleotide
(NADPH) oxidase (DPI), and p38 MAPK (SB203580) in
IRPTCs stably transfected with TGF-b1 (S). Tiron, DPI,
and SB203580 effectively inhibited TGF-b1-induced ANG
mRNA expression (Figure 10). These data confirm that the
molecular pathway mediating the TGF-b1 action on ANG
mRNA expression is mediated, at least in part, via ROS
generation and activation of p38 MAPK in IRPTCs.
TGF-b1 stimulates ANG gene promoter activity in IRPTCs
To determine whether the effect of TGF-b1 on ANG gene
expression is at the transcriptional level in IRPTCs, we
transfected pOCAT (plasmid containing the coding sequence
for chloramphenicol acetyltransferase (CAT) without the
promoter)-John Chan (JC) (rat ANG (rANG) N-1498/þ 18),
a fusion gene containing the rANG gene promoter (1498
nucleotides upstream of the start site of transcription) fused
with a CAT reporter. Figure 11 illustrates that TGF-b1
enhanced rANG gene promoter activity by two fold
(Po0.005) in comparison to control, unstimulated IRPTCs.
Consistent with the mRNA data, the stimulatory effect of
TGF-b1 was inhibited in the presence of tiron, DPI, and
SB203580.
TGF-b1 induces ROS generation and ANG mRNA expression
in mRPTs
To establish whether TGF-b1 could evoke ROS generation
and enhance ANG gene expression in RPTs in vivo, we
incubated freshly isolated mouse renal proximal tubules
(mRPTs) in the absence or presence of TGF-b1 for various
time periods (0, 2, 4, 6, and 8 h) ex vivo. Figure 12 shows that
TGF-b1 evoked ROS generation and enhanced ANG mRNA
expression in mRPTs in a time-dependent manner. These
findings demonstrate that TGF-b1 could elicit ROS genera-
tion and stimulate ANG mRNA expression in RPTs ex vivo.
DISCUSSION
The present study reports an autocrine action of TGF-b1:
stimulation of ANG gene expression in IRPTCs. The
stimulatory effect of TGF-b1 is mediated, at least in
part, via ROS generation, p38 MAPK activation, and p53
expression in IRPTCs.
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TGF-b1 plays an important role in kidney diseases, and its
involvement is far from fully understood.1 As we reported
previously, heightened TGF-b1 gene expression is one of
the outcomes of overexpression of ANG cDNA in IRPTCs,
leading to renin–angiotensin system activation in high
glucose milieu.25 These results indicate that high glucose
induces ANG expression, which is then converted sequen-
tially to Ang I and then to Ang II by IRPTC renin and
angiotensin converting enzyme, respectively. Ang II then
induces TGF-b1 mRNA expression via the AT1-R in IRPTCs.
In proximal tubular cells, TGF-b1 is responsible for collagen
a1 (type IV) production and hypertrophy (likely through
increased p27Kip1).5,25,34–37
In the present study, we demonstrated that active TGF-b1
increases ANG gene expression in IRPTCs. Consistently,
IRPTCs overexpressing TGF-b1 (S) cDNA enhanced ANG
gene expression, whereas diminished basal expression of
ANG mRNA is observed in IRPTCs overexpressing TGF-b1
(AS) cDNA, arguing that TGF-b1 is responsible, at least in
part for ANG gene expression in IRPTCs. These results
suggest the existence of a positive feedback loop, by which
TGF-b1 could enhance its own expression via activation of
intrarenal renin–angiotensin system in vivo.
TGF-b1 has been found to activate various signaling
pathways in different cell lines.6–8,20–23,38,39 To investigate the
underlying mechanism(s) of TGF-b1 action on ANG gene
expression, we assessed the role of ROS formation and p38
MAPK activation, because these mechanisms have been
found to mediate high glucose-induced ANG gene expression
as reported previously.27 Indeed, our data revealed that TGF-
b1 evokes an increase of up to 150–200% of ROS genera-
tion in IRPTCs and IRPTCs overexpressing TGF-b1 (S)
cDNA. This increment of ROS production was confirmed by
augmented PAI-1 mRNA expression (a marker of ROS
generation). The stimulatory effect of TGF-b1 was inhibited
in the presence of DPI, tiron, and SB203580, but not in the
presence of low concentration (109 M) of losartan or
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perindopril. Higher concentrations of losartan (X108 M) or
perindopril (X106 M), however, effectively suppressed TGF-
b1-stimulated ROS generation. These observations are
consistent with those of Hannken et al.40 at high concentra-
tions that losartan does prevent ROS generation stimulated
by Ang II. On the other hand, our data showed that much
higher concentrations of perindopril (X106 M) were
required to inhibit ROS generation stimulated by TGF-b1.
In vitro studies have shown that perindopril possesses a weak
antioxidant activity.41 These observations suggest that TGF-b1,
rather than endogenous intrarenal Ang II, was responsible for
ROS generation in IRPTCs. However, we cannot categorically
exclude the possibility that a small portion of ROS was
generated by endogenous intrarenal Ang II.
Furthermore, we demonstrated a significant elevation
of p53 in IRPTCs treated with active TGF-b1 as well as
in IRPTCs overexpressing TGF-b1 (S) cDNA. These experi-
ments were conducted under normal glucose (5 mM
D-glucose) conditions without serum, excluding any influ-
ences other than those deriving from TGF-b1 alone. These
data are consistent with studies by others that hyperglycemia
can activate p53 and p53-regulated genes, including ANG
gene in myocytes.32,33,42
Our results also revealed that IRPTCs overexpressing and
downexpressing p53 had significantly higher and lower ANG
mRNA expression, respectively, demonstrating that p53 can
indeed influence ANG expression (most probably by binding
to its promoter via the p53-binding site). To further test
whether p53 is essential for ANG upregulation, control
IRPTCs, IRPTCs overexpressing p53 (S) cDNA, and IRPTCs
overexpressing p53 (AS) cDNA were treated with active
TGF-b1 under normal glucose condition. Our data clearly
showed that IRPTCs overexpressing p53 (AS) cDNA were
unable to increase ANG mRNA significantly in the presence
of TGF-b1. In contrast, TGF-b1 further enhanced ANG
mRNA expression in IRPTCs overexpressing p53 (S) cDNA.
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Figure 10 | Effect of TGF-b1 on ANG mRNA expression in the
absence or presence of tiron, DPI, or SB203580. IRPTCs stably
transfected with control pRC/RSV vector or TGF-b1 (S) were plated at
1 104 cells/plate in six-well plates in DMEM supplemented with 5%
FBS in the absence or presence of tiron (104 M), DPI (106 M), or
SB203580 (105 M). The cells were collected after 8 h for RNA
extraction, followed by RT-PCR of ANG and b-actin mRNA expression.
The ratio of ANG mRNA to b-actin mRNA was quantified by Typhoon
densitometry. The graph represents the mean7s.d. of four
independent experiments and each treatment group was
assayed in duplicate.
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Figure 11 | Effect of TGF-b1 on ANG transcription in IRPTCs.
IRPTCs were plated at 1 104 cells/well in six-well plates in DMEM
supplemented with 5% FBS. Then, 1mg of pRSV/CAT or pOCAT-(rANG
N-1498/þ 18) was transiently transfected into the cells. At 16 h after
transfection, the media were replaced by fresh media without serum
in the absence or presence of active TGF-b1 with or without tiron
(104 M), DPI (106 M), or SB203580 (105 M). The cells were harvested
after 24-h incubation, and then assayed for CAT activity. The graph
represents the mean7s.d. of four independent experiments.
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Figure 12 | Effect of TGF-b1 on ROS generation and ANG mRNA
expression in mRPTs. (a) Freshly isolated mPTCs were incubated ex
vivo in serum-free medium in the presence of 5 ng/ml TGF-b1 for 0, 2,
4, 6, or 8 h. Then, the cells were washed and ROS generation was
measured by lucigenin assay. RLU are expressed for 1 mg protein. The
graph represents the mean7s.d. of four independent experiments.
(b) Freshly isolated mPTCs were incubated ex vivo in serum-free
medium in the presence of 5 ng/ml TGF-b1 for 0, 2, 4, 6, or 8 h,
and then harvested for RNA extraction, followed by RT-PCR of ANG
and b-actin mRNA expression.
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This strongly indicates that, at least in IRPTCs, p53 is
essential in the molecular pathway linking TGF-b1 to ANG
gene upregulation.
To confirm more completely that TGF-b1 stimulates
ANG gene expression at the transcriptional level, we tested
our model by transient transfection of the fusion gene
pOCAT-JC (rANG N-1984/þ 18), which contains the
full-length rANG gene promoter fused to a CAT reporter,
in IRPTCs in the absence or presence of tiron, DPI,
or SB203580. Our results demonstrated that tiron, DPI,
and SB203580 effectively blocked the stimulatory effect
of TGF-b1 on ANG gene promoter activity, disclosing
TGF-b1’s action on ANG gene expression at the transcrip-
tional level.
Finally, as IRPTCs are immortalized cells, it would be
important to validate these findings in primary proximal
tubular cells. Therefore, we used freshly isolated mRPTs to
validate the results obtained in IRPTCs. Indeed, our data
showed that TGF-b1 evokes ROS generation and stimulates
ANG mRNA expression, supporting the potential autocrine
effect of TGF-b1 on ANG gene expression in renal proximal
tubular cells in vivo.
At present, we do not know the exact molecular
mechanism(s) by which TGF-b1 activates NAPDH oxidase.
It has been demonstrated that upregulation of subunits of
NAPDH oxidase by TGF-b1 may play an important role in
this activation.43 Similarly, we do not know the molecular
mechanism(s) linking p38 MAPK activation to p53 expres-
sion. A likely explanation is that the activated p38 MAPK
physically associates with p53 and phosphorylates ser 15,
which results in accumulation of p53 protein44 and stimu-
lation of transcription of downstream target genes, including
ANG gene. Clearly, more studies are warranted along
these lines.
In conclusion, the present study demonstrates that
TGF-b1 enhances ANG gene expression, and this effect is
mediated via ROS generation, p38 MAPK activation, and p53
expression. We, therefore, propose the following molecular
pathway for TGF-b1 action on ANG gene expression in
IRPTCs: TGF-b1 activates NADPH oxidase to evoke ROS
generation, p38 MAPK activation, and p53 expression. P53
binds to p53-binding sites in rANG gene promoter and sub-
sequently enhances ANG transcription and Ang II formation.
Such a molecular pathway provides evidence of a positive
autocrine feedback loop for TGF-b1 to modulate ANG
gene expression and renin–angiotensin system activation,
ultimately leading to renal injury.
MATERIALS AND METHODS
Chemicals and constructs
D(þ )-glucose, D-mannitol, tiron (a superoxide scavenger), DPI (an
inhibitor of NADPH oxidase), hydrocortisone, prostaglandin E1,
transferrin, epidermal growth factor, insulin, and mouse anti-b-
actin monoclonal antibodies were purchased from Sigma-Aldrich
Canada Ltd (Oakville, ON, Canada). Active human TGF-b1 and
SB203580 (a p38 MAPK inhibitor) were obtained from R & D
Systems (Hornby, ON, Canada) and CalBiochem Corporation (La
Jolla, CA, USA), respectively. Mouse anti-p53 monoclonal anti-
bodies and goat anti-mouse horseradish peroxidase were procured
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Rabbit
anti-rANG antibodies were raised in our laboratory.45 Percoll
was purchased from Amersham-Pharmacia Biotech (Baie d’Urfe´,
QC, Canada). Normal glucose (5 mM) DMEM (catalog No 12320,
oligonucleotides, the plasmid vector pRC/RSV, and restriction
enzymes were obtained from InVitrogen, Inc. (Burlington,
ON, Canada).
Full-length rat TGF-b1 cDNA and p53 cDNA were cloned from
IRPTCs in our laboratory by conventional reverse transcription-
polymerase chain reaction (RT-PCR) S and AS primers correspond-
ing to nucleotides Nþ 401 to Nþ 424 (50-GCC GCC TCC CCC
ATG CCG CCC TCG-30) and Nþ 1585 to Nþ 1565 (50-TCA GCT
GCA CTT GCA GGA GCG-30) of rat TGF-b146 cDNA, and S and AS
primers corresponding to nucleotides Nþ 1 to Nþ 19 (50-AAA
GCG GCC GCA TGG AGG ATT CAC AGT CGG-30), and Nþ 1176
to Nþ 1156 (50-AAA GCG GCC GCT CAG GCG TAG TCA GGC
ACG TCG TAA GGA ATA GTC TGA GTC AGG CCC CAC-30) of rat
p53 cDNA,47 were used in PCR.
Cell culture
IRPTCs (cell line 93-p-2-1) from passage 11 were studied in stable
gene transfection. The characteristics of this cell line have been
described elsewhere.48 Various concentrations of active human TGF-
b1, according to the range described in the literature,49 were
employed to establish optimal conditions. IRPTCs were cultured in
DMEM containing 5% FBS until they reached 60–70% confluence.
The media were then changed to serum-free DMEM, assuring that
endogenously secreted TGF-b1 would not interfere in the assay.
In serum-free media, secreted TGF-b1 (pan-TGF-b1) should remain
inactive because proteases that would cleave pan-TGF-b1 are
lacking. After a 1-h preincubation period, TGF-b1 was added
(considered time 0 h) in concentrations ranging from 0 to 10 ng/ml
and incubated for various time periods up to 24 h. Cells were then
harvested and assayed for ROS generation and ANG mRNA
expression (described below).
Isolation of mRPTs
Male mice (C57BL/6) at 4–6 weeks of age were euthanized with CO2.
Their kidneys were removed, rinsed in ice-cold DMEM and
decapsulated, and the cortices were separated from the medulla.
Proximal tubules were isolated by Percoll gradient50 with slight
modifications as described previously.51 Aliquots of freshly isolated
mRPTs from individual mice were immediately used for total RNA
isolation. The remaining mRPTs were then pooled, suspended in
culture medium (50% DMEM, 50% F-12 DMEM, 0.05 mM
hydrocortisone, 25 ng/ml prostaglandin E1, 5 mg/ml transferrin,
10 ng/ml epidermal growth factor, and 5 mg/ml insulin), then
incubated ex vivo at 371C in the absence or presence of 5 ng/ml
activated TGF-b1 for 0, 2, 4, 6, or 8 h. At the end of the incubation
period, mRPTs were harvested and assayed for ROS generation and
ANG mRNA expression.
ROS generation
Cellular ROS production was quantified by the lucigenin method
with minor modifications as described previously.27 ROS generated
in mRPTs were normalized with protein concentration and is
expressed as relative light units per mg protein.
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Western blot analysis
Cell lysates dissolved in lysis buffer (described above) were
centrifuged at 13 000 g and 41C. The supernatants (50–100 mg
proteins) were loaded on sodium dodecyl sulfate-12% polyacryla-
mide gel. After transfer by wet blotting onto a polyvinylidine
difluoride membrane (Hybond-P, Amersham-Pharmacia Biotech),
it was blocked in 5% non-fat milk powder and 0.05% Tween 20 in
phosphate-buffered saline. The membrane was first blotted with
rabbit polyclonal antibodies anti-rANG45 or mouse anti-p53, and
then re-blotted with anti-b-actin monoclonal antibodies and
chemiluminescent developing reagent (Roche Biochemicals, Inc.).
The relative densities of rANG, p53, and b-actin bands were quanti-
fied by computerized laser densitometry (ImageQuant software
(version 5.1), Molecular Dynamics, Sunnyvale, CA, USA).
Stable DNA transfection
IRPTCs were transfected using Lipofectamine reagent according to
the supplier’s instruction (InVitrogen, Inc.). We optimized the DNA
concentration for gene transfection at 1–2 mg per 1 106 cells. Stable
transformants were selected in the presence of geneticin (G418)
(500 mg/ml) (InVitrogen, Inc.) according to the methodology we
have described elsewhere.25
RT-PCR
Total RNA was used in RT-PCR to quantify the amount of ANG and
PAI-1 (a gene inducible by intracellular RO22) mRNA expressed in
IRPTCs and mRPTs. Briefly, 2 mg total RNA was taken to synthesize
first-strand cDNAs by employing the SuperScript preamplification
system (InVitrogen, Inc.). Then, the first-strand cDNA was diluted
with water to a ratio of 1:4, and the aliquots were processed to
amplify ANG, PAI-1, and b-actin cDNA fragments with the PCR
core kit according to the supplier’s instructions (InVitrogen, Inc.) as
described previously.50 The forward primer 50-CCT CGC TCT CTG
GAC TTA TC-30 and the reverse primer 50-CAG ACA CTG AGG
TGC TGT TG-30, corresponding to nucleotide sequences Nþ 676 to
Nþ 695 and Nþ 882 to Nþ 901 of rANG cDNA52 or mouse ANG
cDNA,53 were used in the RT-PCR assays. Similarly, primers specific
for rat PAI-1 cDNA54 (forward and reverse primers 50-CTC ATC
AGA CAA TGG AAG AGC-30 and 50-CAT CAG CTG GCC CAT GAA
GAG-30, corresponding to nucleotides Nþ 959 to Nþ 979 and
Nþ 1318 to Nþ 1298 of rat PAI-1 cDNA (Accession number:
M24067)) and b-actin cDNA55 (forward and reverse primers 50-ATG
CCA TCC TGC GTC TGG ACC TGG C-30 and 50-AGC ATT TGC
GGT GCA CGA TGG AGG G-30, corresponding to nucleotides
Nþ 155 to Nþ 179 of exon 3 and nucleotide Nþ 115 to Nþ 139 of
exon 5 of rat b-actin) were employed for RT-PCR assay.
To identify ANG, PAI-1, and b-actin cDNA fragments, 10 ml of
the PCR product was electrophoresed on 1.2% agarose gels, then
transferred onto a Hybond XL nylon membrane (Amersham-
Pharmacia Biotech). Digoxigenin -labeled oligonucleotides 50-GAG
GGG GTC AGC ACG GAC AGC ACC-30 and 50-GCA CAA GCA
CTA CAA AAG GTC-30, corresponding to nucleotides Nþ 775 to
Nþ 798 of rANG cDNA52 and Nþ 1139 to Nþ 1159 of PAI-1
cDNA,54 were prepared with a digoxigenin oligonucleotide 30-end
labeling kit (Roche Biochemicals, Inc.), and hybridized the PCR
products on the membrane. After stringent washing, the membrane
was processed with a digoxigenin chemiluminescent detection kit
(Roche Biochemicals, Inc.) and exposed to Kodak BMR film
(Eastman Kodak Company, Rochester, NY, USA). After ANG mRNA
analysis, the membrane was stripped and rehybridized with a b-actin
oligonucleotide probe (sequence 50-TCC TGT GGC ATC CAT GAA
ACT ACA TTC-30, corresponding to nucleotides Nþ 9 to Nþ 35 of
exon 4 of the rat b-actin gene).55 ANG mRNA levels were
normalized by the corresponding b-actin mRNA levels.
CAT assay
The method of construction of the rANG gene promoter–CAT
fusion gene, pOCAT (rANG N-1498/þ 18), has been described
previously.29 Plasmid or the rANG–CAT fusion gene was transfected
into IRPTCs using Lipofectamine reagent.
In the present study, a total of 1 mg supercoiled DNA (i.e. 1 mg
pOCAT (rANG N-1498/þ 18) or 1 mg pRSV/CAT) was employed
routinely in cell transfection. At 16 h after transfection, the culture
media were replaced by fresh serum-free media containing 5 mM
D-glucose with or without active TGF-b1 in the absence or presence
of DPI, tiron, or SB203580. The cells were harvested 24 h later and
assayed for CAT activity.29
To normalize the efficiency of transfection, 0.1 mg pTK/hGH (a
vector with the thymidine kinase enhancer/promoter fused to the
50-human growth hormone gene) was cotransfected with 1 mg
pOCAT (rANG N-1498/þ 18) or pRSV/CAT.29 The plasmid pRSV/
CAT served as a positive control to monitor the transfection
efficiency of the rANG–CAT fusion gene in the absence of added
drugs. The level of transfection efficiency for pRSV/CAT in IRPTCs
ranged from 60 to 90%, that is the percentage of 14C-chloramphe-
nicol conversion to mono and diacetyl chloramphenicol. The
transfection efficiency of pOCAT (rANG N-1498/þ 18) in IRPTCs
ranged from 25 to 35%, compared to pRSV/CAT. The inter- and
intra-assay coefficient variations of transfection for pOCAT (rANG
N-1498/þ 18) in IRPTCs were 25 and 12% (n¼ 10), respectively.
Statistical analysis
Three to four separate experiments were performed per protocol,
and each treatment group was assayed in duplicate or triplicate. The
data were analyzed by Student’s t-test with EXCEL statistics. A
probability level of Pp0.05 was considered to be statistically
significant (*Po0.05, **Po0.01, ***Po0.005).
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